BJP CPD Online e-learning site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Psychiatric Bulletin Advances in Psychiatric Treatment All RCPsych Journals
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lichtshtein, D.
Right arrow Articles by Belmaker, R. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lichtshtein, D.
Right arrow Articles by Belmaker, R. H.

The British Journal of Psychiatry 132: 145-148 (1978)
© 1978 The Royal College of Psychiatrists

Gamma-aminobutyric acid (GABA) in the CSF of schizophrenic patients before and after neuroleptic treatment

D Lichtshtein, J Dobkin, RP Ebstein, J Biederman, R Rimon and RH Belmaker

Gamma-aminobutyric acid (GABA) levels in the CSF were measured in 9 normal individuals, 17 drug-free schizophrenic patients and 10 of these same schizophrenic patients after neuroleptic treatment. There was no significant difference between CSF level of GABA in the control group compared to those in schizophrenic patients; however, 6 of the 7 lowest GABA levels were from schizophrenic patients. There was a significant decline of 12 per cent in mean GABA levels in the CSF after a mean of two months of neuroleptic treatment.


This article has been cited by other articles:


Home page
 J PsychopharmacolHome page
R. Wolf, F. Strehle, and H. M. Emrich
In vivo effects of carbamazepine and haloperidol on GABA neurotransmission and LH secretion
J Psychopharmacol, January 1, 1995; 9(1): 25 - 31.
[Abstract] [PDF]

Home page
 Arch Gen PsychiatryHome page
D. P. van Kammen, D. E. Sternberg, T. A. Hare, R. N. Waters, and W. E. Bunney Jr
CSF Levels of {gamma}-Aminobutyric Acid in Schizophrenia: Low Values in Recently Ill Patients
Arch Gen Psychiatry, January 1, 1982; 39(1): 91 - 97.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
T. A. Hare, J. H. Wood, and B. V. Manyam
Clinical Implications of Enzyme-Mediated Alterations of {gamma}-Aminobutyric Acid Content in Human CSF
Arch Neurol, August 1, 1981; 38(8): 491 - 494.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Psychiatric Bulletin Advances in Psychiatric Treatment All RCPsych Journals
Copyright © 1978 The Royal College of Psychiatrists.